Abstracts tagged "Gout and utilization review"

Abstract Number: 2125 • 2014 ACR/ARHP Annual Meeting
Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study
Louis Bessette¹, Frédéric Lioté², Carmen Moragues³, Rüdiger Moericke⁴, Zhang Zhiyi⁵, Alberto Ferreira⁶, Pascal Lecomte⁶, Sophia Kessabi⁶, Haijun Tian⁷ and Jasvinder A. Singh^8,9, ¹CHUL, Quebec, QC, Canada, ²Hôpital Lariboisière & University Paris Diderot, Paris, France, ³Hospital Platón, Barcelona, Italy, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Mayo Clinic, Rochester, MN, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Refractory gouty arthritis (RGA) is a condition characterized by appearance of recurrent flares and contraindication, intolerance, or lack of efficacy to first-line anti-inflammatory therapy…
Abstract Number: 1997 • 2013 ACR/ARHP Annual Meeting
Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study
Jasvinder A. Singh^1,2, Aseem Bharat³, Puja Khanna⁴, Cleopatra Aquino-Beaton⁵, Jay E. Persselin⁶, Erin Duffy⁷, David Elashoff⁸ and Dinesh Khanna⁹, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Because of the chronic nature of the disease, gout is associated with more co-morbidities, poor health-related quality of life (HRQoL) and more healthcare utilization…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].